|
Real-time Estimate
Cboe BZX
21:45:13 28/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 22.95 USD | -0.22% |
|
-0.48% | -50.75% |
| 10-20 | Collegium Pharmaceutical Settles Nucynta Patent Litigation for $17 Million | MT |
| 10-10 | Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says | MT |
| Market Cap | 749M 672M 621M 563M 1.05B 71.12B 1.06B 7.44B 2.95B 37.28B 2.81B 2.75B 118B | P/E 2026 * |
20.6x | P/E 2027 * | 6.44x |
|---|---|---|---|---|---|
| Enterprise Value | 749M 672M 621M 563M 1.05B 71.12B 1.06B 7.44B 2.95B 37.28B 2.81B 2.75B 118B | EV / Sales 2026 * |
0.9x | EV / Sales 2027 * | 0.89x |
| Free-Float |
77.39% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| COLL | Delayed | |
CBOE
| COLL | Real-time | |
|
Boerse Muenchen
| 354 | Real-time | |
|
Deutsche Boerse AG
| 354 | Delayed | |
|
Börse Stuttgart
| 354 | Delayed | |
|
Tradegate
| 354 | Real-time |
Last Transcript: Collegium Pharmaceutical, Inc.
| 1 day | -0.22% | ||
| 1 week | -0.48% | ||
| Current month | +4.51% | ||
| 1 month | +0.77% | ||
| 3 months | -36.48% | ||
| 6 months | -30.49% | ||
| Current year | -50.75% |
| 1 week | 22.15 |  | 23.84 |
| 1 month | 21.43 | | 24.04 |
| Current year | 21.43 | | 49.31 |
| 1 year | 21.43 | | 50.79 |
| 3 years | 21.11 | | 50.79 |
| 5 years | 14.04 | | 50.79 |
| 10 years | 7.37 | | 50.79 |
| Manager | Title | Age | Since |
|---|---|---|---|
Vikram Karnani
CEO | Chief Executive Officer | 51 | 12/11/2024 |
Colleen Tupper
DFI | Director of Finance/CFO | 50 | 24/05/2021 |
Thomas Smith
CTO | Chief Tech/Sci/R&D Officer | 65 | 23/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Gino Santini
CHM | Chairman | 69 | 15/05/2025 |
John Freund
BRD | Director/Board Member | 72 | 01/02/2014 |
Garen Bohlin
BRD | Director/Board Member | 78 | 01/01/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/5/26 | Sell | Director | -20 | 0.0001% | ||
| 15/5/26 | Exercice | Director | 21,527 | 0.0664% | ||
| 14/5/26 | Free | Director | 8,741 | 0.0270% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.22% | -0.48% | -35.60% | +5.00% | 749M | |
| +0.58% | +0.24% | +55.33% | +125.18% | 1,143B | |
| -0.12% | +3.25% | +42.38% | +81.02% | 647B | |
| -0.37% | -0.30% | +24.79% | +100.11% | 506B | |
| -0.21% | +1.02% | +51.67% | +64.11% | 384B | |
| -0.11% | -5.67% | +62.45% | +37.69% | 350B | |
| +0.89% | +1.45% | +30.19% | +52.10% | 293B | |
| +0.06% | +0.87% | +2.56% | +24.53% | 265B | |
| +0.22% | +1.22% | +51.91% | +68.59% | 242B | |
| -0.12% | +2.72% | +33.81% | +102.83% | 197B | |
| Average | +0.07% | +0.66% | +31.95% | +66.11% | 402.83B | |
| Weighted average by Cap. | +0.16% | +0.71% | +43.11% | +85.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 833M 748M 690M 626M 1.17B 79.13B 1.18B 8.28B 3.29B 41.48B 3.13B 3.06B 132B | 845M 758M 700M 635M 1.19B 80.22B 1.2B 8.39B 3.33B 42.05B 3.17B 3.1B 133B |
| Net income | 28.73M 25.78M 23.81M 21.59M 40.35M 2.73B 40.84M 285M 113M 1.43B 108M 106M 4.54B | 83.33M 74.79M 69.06M 62.62M 117M 7.92B 118M 828M 329M 4.15B 313M 306M 13.16B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | US$22.81 | -0.85% | 6,995 |
| 27/10/26 | US$23.00 | -0.90% | 486,611 |
| 26/10/26 | US$23.21 | +1.09% | 518,254 |
| 23/10/26 | US$22.96 | -2.30% | 662,374 |
| 22/10/26 | US$23.50 | +2.55% | 738,765 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- COLL Stock
Select your edition
All financial news and data tailored to specific country editions
